Novo Nordisk, a leader in breakthrough hemostasis research and treatment, today announced the appointment of Neal C. Fitzpatrick as national sales director of biopharmaceuticals; specifically the hemostasis and growth hormone therapeutic areas. In this leadership position, Fitzpatrick will build and lead Novo Nordisk’s national sales capabilities and play a key role in expanding Novo Nordisk’s presence and encouraging future innovation-driven growth.
Eddie Williams, vice president of biopharmaceuticals said, "Adding an individual of Neal’s caliber signifies another high point in the growth of Novo Nordisk and our biopharmaceuticals unit. Neal’s knowledge of the industry and experience with corporate growth will be an extraordinary asset, and he will help us to reach our ambitious aspirations now and in the coming years. Neal has a passion for addressing the needs of physicians and their patients with hemophilia, and will share this passion in the growth hormone deficiencies therapeutic area as well. I am excited about bringing Neal on our team."
